Skip to main content

Table 1 Patient drug exposure summary

From: Identification of gene-drug interactions that impact patient survival in TCGA

Patient numbers

Drug

LGG

GBM

LGG + GBM

Temozolomide

241

239

580

Bevacizumab

41

92

133

Lomustine

32

49

84

Irinotecan

16

60

76

Dexamethasone

0

60

60

Carmustine

12

39

51

Gliadel Wafer

5

35

40

Etoposide

10

28

38

Procarbazine

17

22

39

  1. Total numbers of patients in each cancer type who have been exposed to each drug. Only drugs with 30 or more total patients exposed between both cancer types are shown
Back to article page

BMC Bioinformatics

ISSN: 1471-2105

Contact us